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It is a sign of the times that most of the buzz around 
genomic medicine has more to do with personalized 
medicine than public health [1]. Th is is perhaps con sis-
tent with the prevailing economic sentiment in developed 
countries that benefi ts accruing to the few gradually 
transfer to the majority. Healthy societies also take steps 
to ensure that there is equitable distribution of wealth, 
which should be construed to include much more than 
fi nancial wellbeing. We can thus ask to what extent 
genomics can be used to improve the prospects of as 
many people as possible.
For perspective, consider the public health benefi ts that 
are generally considered to have had the greatest impact 
globally. Rather than individualized treatments, these are 
things like access to fresh water, closed sewage systems, 
better knowledge of hygiene, widespread antibiotic usage, 
mosquito nets, and education of women. More recently, 
recording patients’ family medical history, the adoption 
of electronic medical records, and the trend toward 
standardization of medical care on the basis of evidence 
of effi  cacy are all set to benefi t a large number of people, 
at least in developed countries. What are the genomic 
equivalents?
Th e poster child for successful personalized genomics 
is the case of the Beery twins [2]. Diagnosed early in life 
with DOPA-responsive dystonia, but incompletely res-
pon sive to dopamine therapy, the discovery of compound 
heterozygous mutations in their sepiapterin reductase 
gene led to supplementation with the serotonin precursor 
5-hydroxytryptophan, which turned the twins’ lives 
around. Early adopters of whole-exome sequencing in the 
context of congenital pediatric defects, including cilio-
pathies, craniofacial abnormalities, primary immune 
defi ciencies and developmental delay, report impressive 
levels of success in identifying causal mutations, bringing 
peace of mind to parents and in some cases suggesting 
new medical interventions. And cancer treatment is 
already being reshaped by the deep sequencing of tumor 
genomes and transcriptomes, with the objective of 
identifying the most suitable chemotherapeutic targets in 
refractory cases [3]. Extraordinary and transformative as 
these achievements are, it is hard to imagine them 
directly benefi ting more than a minority - perhaps 5% - of 
the population. However, we can see fi ve ways in which 
personal genomics may generalize to public health 
genomics.
(1) Trickle-down genomics. No doubt the most likely 
development arising from personal genomics will be a 
gradual expansion of the number of people whose 
personal genomes become a part of their individualized 
treatment. Th e next frontier may be genomic risk 
assessment for adult-onset congenital decline, but we will 
also see the extension of health benefi ts from probands to 
family members. In this context, it is worth highlighting a 
recent report from 23andMe [4] that the discovery of 
BRCA1 or BRCA2 mutations in 32  people led to the 
detection of the mutations in 13 of 30 relatives of these 
people who chose follow-up evaluation, with an overall 
conversion of initial anxiety into positive outcomes.
(2) Biological knowledge. In their review of the fi rst 
fi ve years of genome-wide association studies (GWAS), 
Visscher et al. [5] countered the perception in some 
circles that common variant analysis has had little utility 
because it is rarely clinically actionable, by observing the 
gains in knowledge of new biology have been unprece-
dented. It is doubtful whether many scientists, if they had 
been told 10 years ago that the investment of half a billion 
dollars would lead to the discovery of over 100 independent 
loci for each of the common diseases that aﬄ  ict humans, 
would have baulked at the expenditure. Th e discoveries 
have highlighted new cellular and molecular mechanisms, 
informed us about the architecture of disease, and in 
time will surely translate into new medical care options 
for diseases that collectively aﬄ  ict more than half the 
population.
(3) Wellness genomics. Genomic profi ling can already 
facilitate personal risk assessment not just for people 
with overt disease, but also for healthy individuals, 
particularly middle-aged adults as they begin to deal with 
medical issues. Some will age gracefully, but most will 
encounter pain and loss of organ function that will 
severely constrain their lifestyle, so one objective for 
personalized medicine should be helping people to make 
better health decisions [6]. Th is is in fact one of the © 2010 BioMed Central Ltd
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motivations for medical genomic profiling companies, to 
promote self-knowledge and thereby change the culture 
from one of ‘doctor, I’m sick, make me better’ to one of 
‘the more informed I am, the better decisions I can make 
for myself ’. Society also has an interest in shifting the 
burden from government programs to individual respon-
sibility. Genetics alone will never be accurately predictive 
for most conditions, and many challenges remain in the 
interpretation and communication of information 
between patients and physicians [7]. However, combined 
with functional genomic, environmental and clinical 
profiles, genomic profiling has the potential to classify 
elevated risk, which may be useful for each one of us.
(4) Genomics of disease progression. So far, both 
GWAS and genome sequencing have focused on the 
genetic basis of the onset of disease and its causes. Yet 
clinically, arguably the more important need for personal 
profiling is in understanding how disease progresses: why 
do some patients go into remission whereas others 
constantly battle flares and relapses? Pain and depression 
are equally important aspects of patient experience, yet 
have received little attention from genomicists. On this 
note, it is striking that the number one source of mor-
bidity, lower back pain, is completely absent from the 
GWAS catalog, despite at least anecdotal heritability [8]. 
Relatedly, there are a growing number of pharmaco-
genetic tests to assess personal response to drugs, and 
there is also ample room for assessing response to other 
types of interventions, including dietary change and 
medical devices.
(5) Global health genomics. Given the epidemiological 
transition globally from infectious and nutritional disease 
to the Western profile of metabolic, immunological, 
cognitive, and age-related diseases [9], there seems to be 
a moral obligation to ensure that advances in the 
developed world are quickly transferred to developing 
countries. Cost and sheer numbers, not to mention 
priorities and infrastructure, mean that personal genomics 
will only be accessible to a tiny minority for the near 
future, underscoring the imperative to ensure that the 
benefits of medical genomics are transferred through 
indirect mechanisms. First-rate genome research institu-
tions are emerging all over the world, and international 
networks connect researchers globally, so the conceptual 
challenge is how to partner traditional medical programs 
with genome-oriented public health programs [10]. We 
envisage, for example, initiatives that use genomics to 
characterize the identity and physiological impact of 
environ mental toxins, to enhance newborn screening 
directed at early interventions, and to target scarce 
medical resources to the most at risk individuals and 
those most likely to respond to treatment.
Contemporary human genetics faces a tension between 
discovery genetics, performed most efficiently at the 
scale of N = 100,000, and translational medical genetics, 
performed necessarily at N = 1. As we learn how to read 
individual genomes, it is natural that attention will focus 
initially on large-effect rare variants, as these are 
considered to be most likely to define clinical targets. Yet 
basic quantitative genetics tells us that the reasons why 
brothers resemble sisters, and why populations differ in 
disease prevalence, have more to do with the genetic 
polymorphisms we share than the mutations we own 
privately. Harnessing this insight, in ways we can only 
begin to perceive, has the potential to achieve substantial 
economic and public health efficiencies. Because our 
genetic and environmental backgrounds remain essential 
components of risk, familiarity with the common genome 
is one key to ensuring that genomics becomes a public 
health enterprise.
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